头颈部腺样囊性癌粒子治疗的系统综述
该系统综述纳入44项研究,评估快中子、质子束和碳离子放疗对头颈部腺样囊性癌的疗效与毒性。结果显示质子束和碳离子放疗的局部控制率优良且毒性可接受,被认为是首选放疗方式。
要点
- 质子束和碳离子放疗局部控制率优良,毒性可接受。
- 快中子治疗局部控制率相对较低。
- 常见毒性包括黏膜炎、皮炎、脑/骨坏死及视听异常。
核心结论
- 质子束和碳离子放疗是头颈部腺样囊性癌的首选放疗方式,在辅助和根治设置中局部控制率优良且毒性可接受。
研究设计与样本
- 系统综述遵循PRISMA指南,纳入44项研究(6项快中子、16项质子束、12项碳离子、10项多粒子),其中41项回顾性、3项前瞻性。
主要发现
- 快中子连续治疗5年局部控制率和总生存率分别为57%和72%,独立治疗5年分别为61%和89.4%。
- 质子束治疗腺样囊性癌2年局部控制率94%、5年总生存率76%;混合组织学2年局部控制率89%、3年总生存率77.7%。
- 碳离子治疗腺样囊性癌5年局部控制率和总生存率分别为68.6%和74%;混合组织学5年分别为68%和59.7%。
- 最常见毒性为黏膜炎、皮炎、脑/骨坏死及视觉/听觉异常。
临床怎么用
- 对于头颈部腺样囊性癌,优先考虑质子束或碳离子放疗,尤其在辅助和根治设置中。
局限性
- 纳入研究多为回顾性,仅3项前瞻性研究,证据等级有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Determine efficacy (local control, overall survival, and toxicities) of particle-based therapy (fast neutron therapy (FNT), proton beam therapy (PBT), carbon ion radiotherapy (CIRT)) in the treatment of adenoid cystic carcinomas (ACCs) of the head and neck. METHODS: This systematic literature review was conducted with adherence to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. All published work on the treatment of ACCs through particle-based treatment modalities (FNT, PBT, CIRT) with adequate reporting of patient outcomes in the English language were considered eligible for this systematic review. RESULTS: 44 studies (6 FNT, 16 PBT, 12 CIRT, and 10 multiple particles) reporting on ACC patient outcomes following particle therapy were included in this review. There were 41 retrospective and 3 prospective studies. Each particle modality was split into 2 series to ensure equitable evaluation. The median local control (LC) and overall survival (OS) rates were as follows: FNT consecutive 5-year 57 % & 72 %, FNT independent 5-year 61 % & 89.4 %, PBT ACC 2-year 94 % & 5-year 76 %, PBT mixed histology 2-year 89 % & 3-year 77.7 %, CIRT ACC 5-year 68.6 % & 74 %, and CIRT mixed histology 5-year 68% & 59.7%. The most common toxicities across the modalities were mucositis, dermatitis, brain/bone necrosis, and visual/auditory abnormalities. CONCLUSION: This literature review suggests that PBT and CIRT are the preferred RT modality for ACC treatment with excellent LC rates and acceptable toxicity profiles in the adjuvant and definitive setting.
引用
- Rohit A, Bates JE, Frank SJ, et al. A systematic review of particle-based treatment modalities for adenoid cystic carcinomas of the head and neck. Radiother Oncol. 2025. PMID: 40876761. doi:10.1016/j.radonc.2025.111115
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。